Barrington Research Maintains Outperform on US Physical Therapy, Raises Price Target to $122
U.S. Physical Therapy, Inc. Reports Third Quarter 2026 Results and Reaffirms EBITDA Guidance of $102 million to $106 million
The 5 most interesting analyst questions from U.S. Physical Therapy’s Q3 2026 earnings call
U.S. Physical Therapy Q3 Earnings Call Highlights
U.S. Physical Therapy, Inc. Reports Third Quarter 2026 Results
U.S. Physical Therapy (USPH) Jumped, What Is Behind The Latest Attention?
Barrington Research Maintains Outperform on US Physical Therapy, Raises Price Target to $110
US Physical Therapy Inc (USPH) (Q3 2026) Earnings Call Highlights: Record Visits and Revenue ...
US Physical Therapy (USPH) Q3 2026 Earnings Call Transcript
U.S. Physical Therapy, Inc. (USPH) Q3 2026 Earnings Call Transcript
US Physical Therapy Q3 2026 Earnings Call Transcript
U.S. Physical Therapy (NYSE:USPH) Q3 2026 Results: EPS Beat, Revenue In Line, Shares Rise
Here's What Key Metrics Tell Us About U.S. Physical Therapy (USPH) Q3 Earnings
U.S. Physical Therapy (NYSE:USPH) reports strong Q3 2026
U.S. Physical Therapy: Q3 Earnings Snapshot
USPH Reports Third Quarter 2026 Results, Record High Visits and Revenue Per Visit
US Physical Therapy Q3 Adj. EPS $0.80 Beats $0.76 Estimate, Sales $222.558M Beat $214.536M Estimate
U.S. Physical Therapy (USPH) Stock May Be Overvalued As Sales Face The Test
3 Reasons USPH is risky and 1 stock to buy instead
U.S. Physical Therapy, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call Dates
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.